美国成人社区获得性肺炎住院患者肺炎链球菌流行病学
本研究为2013-2016年美国10城市21家医院的观察性前瞻性监测,纳入12,055例影像学确诊的成人社区获得性肺炎住院患者。结果显示PCV13血清型在全部患者中检出率为4.6%,≥65岁人群为4.2%,18-64岁人群为3.8-5.3%。结论认为儿童接种PCV13后成人仍存在持续的PCV13型CAP负担。
要点
- 美国成人CAP住院患者中PCV13血清型检出率为4.6%。
- ≥65岁患者PCV13血清型检出率为4.2%。
- 18-64岁患者PCV13血清型检出率随风险状态为3.8-5.3%。
核心结论
- 美国儿童PCV13接种项目实施后,尽管成人存在群体保护,PCV13型CAP负担仍持续存在。
研究设计与样本
- 观察性前瞻性监测研究,2013年10月至2016年9月从美国10个地理分散城市的21家急性护理医院招募≥18岁住院成人。
主要发现
- 15,572名入组者中12,055例影像学确诊CAP患者纳入最终分析,平均年龄64.1岁,52.7%为≥65岁。
- 常见合并症包括慢性阻塞性肺疾病(43.0%)和糖尿病(28.6%)。
- PCV13血清型在全部患者中检出552/12,055(4.6%),在≥65岁患者中检出265/6,347(4.2%)。
- 18-64岁患者中PCV13血清型检出率依风险状态为3.8-5.3%。
临床怎么用
- 提示临床医生应关注成人CAP中PCV13血清型的持续负担,为免疫策略提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few studies have measured the burden of adult pneumococcal disease after the introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into the US infant vaccination schedule. Further, most data regarding pneumococcal serotypes are derived from invasive pneumococcal disease (IPD), which represents only a fraction of all adult pneumococcal disease burden. Understanding which pneumococcal serotypes cause pneumonia in adults is critical for informing current immunization policy. The objective of this study was to measure the proportion of radiographically-confirmed (CXR+) community-acquired pneumonia (CAP) caused by PCV13 serotypes in hospitalized US adults. METHODS: This observational, prospective surveillance study recruited hospitalized adults aged ≥18 years from 21 acute care hospitals across 10 geographically-dispersed cities in the United States between October 2013 and September 2016. Clinical and demographic data were collected during hospitalization. Vital status was ascertained 30 days after enrollment. Pneumococcal serotypes were detected via culture from the respiratory tract and normally-sterile sites (including blood and pleural fluid). Additionally, a novel, Luminex-based serotype-specific urinary antigen detection (UAD) assay was used to detect serotypes included in PCV13. RESULTS: Of 15,572 enrolled participants, 12,055 eligible patients with CXR+CAP were included in the final analysis population. Mean age was 64.1 years and 52.7% were aged ≥65 years. Common comorbidities included chronic obstructive pulmonary disease (43.0%) and diabetes mellitus (28.6%). PCV13 serotypes were detected in 552/12,055 (4.6%) of all patients and 265/6347 (4.2%) of those aged ≥65 years. Among patients aged 18-64 years PCV13 serotypes were detected in 3.8-5.3% of patients depending on their risk status. CONCLUSIONS: After implementation of a pneumococcal conjugate vaccination program in US children, and despite the herd protection observed in US adults, a persistent burden of PCV13-type CAP remains in this population.
引用
- Isturiz RE, Ramirez J, Self WH, et al. Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia. Vaccine. 2019. PMID: 31072732. doi:10.1016/j.vaccine.2019.04.087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。